

Sanofi  
Form 6-K  
February 05, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2013**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

Edgar Filing: Sanofi - Form 6-K

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If ☐ Yes ☐ marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In February 2013, Sanofi issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated January 29, 2013: Genzyme and Isis Announce FDA Approval of KYNAMRO (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia
Exhibit 99.2	Press release dated February 4, 2013: Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 5, 2013

SANOFI

By

/S/ John Felitti

Name: John Felitti

Title: Associate Vice President, Corporate Law, Financial &  
Securities Law

**Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated January 29, 2013: Genzyme and Isis Announce FDA Approval of KYNAMRO (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia
Exhibit 99.2	Press release dated February 4, 2013: Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe